HLB Genex, Inc. Logo

HLB Genex, Inc.

Develops and produces customized enzyme and microbiome-based solutions.

187420 | KO

Overview

Corporate Details

ISIN(s):
KR7187420005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노1로 65(관평동), 대전광역시

Description

HLB Genex, Inc. is a biotechnology company that develops and produces customized enzyme and microbiome-based solutions. The company's core activities involve the research, development, and manufacturing of industrial special enzymes and bio-healthcare ingredients. Its key products include enzymes like Lactase for food applications, Catalase for eco-friendly industrial processes, and Proteinase K for molecular diagnostics. In the bio-healthcare segment, it produces Vitamin K2 (Menaquinone 7) for bone and cardiovascular health and Phytosphingosine for cosmeceuticals. The company utilizes proprietary platform technologies, such as Microbial Surface Display and Spore Biologics, to develop its products and advance its pipeline of microbiome therapeutics by identifying effector molecules, also known as postbiotics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-11-22 00:00
[기재정정]주주총회소집결의 (임시주주총회)
Korean 23.6 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.5 MB
2024-11-12 00:00
주식등의대량보유상황보고서(일반)
Korean 78.5 KB
2024-11-01 00:00
주식등의대량보유상황보고서(일반)
Korean 87.6 KB
2024-10-31 00:00
주식등의대량보유상황보고서(일반)
Korean 79.6 KB
2024-10-31 00:00
최대주주변경을수반하는주식담보제공계약체결
Korean 19.8 KB
2024-10-29 00:00
주요사항보고서(전환사채권발행결정)
Korean 63.8 KB
2024-10-29 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 68.4 KB
2024-10-28 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2024-10-28 00:00
경영권변경등에관한계약체결
Korean 16.1 KB
2024-10-28 00:00
주주총회소집결의 (임시주주총회)
Korean 6.0 KB
2024-10-28 00:00
주요사항보고서(유상증자결정)
Korean 74.9 KB
2024-10-07 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 12.6 KB
2024-10-02 00:00
주요사항보고서(타법인주식및출자증권양도결정)
Korean 19.7 KB
2024-08-14 00:00
반기보고서 (2024.06)
Korean 1.5 MB

Automate Your Workflow. Get a real-time feed of all HLB Genex, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Genex, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Genex, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioversys N Logo
Clinical-stage biopharma developing antibacterial therapies for antimicrobial resistance.
Switzerland
BIOV
BIOVIE INC. Logo
Develops drug therapies for neurological disorders and advanced liver disease.
United States of America
BIVI
BioXcel Therapeutics, Inc. Logo
Biopharmaceutical company using AI to develop drugs for neuroscience and immuno-oncology.
United States of America
BTAI
Black Diamond Therapeutics, Inc. Logo
Develops precision oncology therapies targeting families of oncogenic mutations.
United States of America
BDTX
BL Pharmtech Corp. Logo
Researches, develops, and sells health foods, supplements, and pharmaceuticals.
South Korea
065170
BNC Korea Co, Ltd Logo
Develops hyaluronic acid-based dermal fillers and botulinum toxin injectables.
South Korea
256840
Boditech Med Inc. Logo
Develops, manufactures, and distributes in-vitro diagnostic (IVD) solutions.
South Korea
206640
BOIRON Logo
A family-owned pharmaceutical laboratory and a world leader in homeopathic medicines.
France
BOI
Manufactures specialty ingredients for the food, pharmaceutical, and cosmetic industries.
South Korea
002760
Bolt Biotherapeutics, Inc. Logo
Clinical-stage biotech developing immuno-oncology therapies using the innate immune system.
United States of America
BOLT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.